Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026PRNewsWire · 14 min ago
Citius Pharmaceuticals to Participate in October 2026 Investor ConferencesPRNewsWire · Oct 12, 2026
Citius Pharmaceuticals to Participate in September 2026 Investor ConferencesPRNewsWire · Sep 3, 2026
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire · Aug 14, 2026
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire · Aug 14, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan PeriPRNewsWire · Aug 12, 2026Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.07 | -$0.08 | Miss |
| May 15, 2026 | -$0.01 | -$0.27 | Miss |
| Feb 13, 2026 | -$0.04 | -$0.06 | Miss |
| Dec 23, 2025 | -$0.06 | -$0.06 | Beat |
| Aug 12, 2025 | -$0.15 | -$0.08 | Beat |
| May 14, 2025 | -$0.09 | -$0.11 | Miss |